Research programme: bioavailability enhanced therapeutics - Samyang

Drug Profile

Research programme: bioavailability enhanced therapeutics - Samyang

Alternative Names: Aprepitant BA - Samyang; Candesartan BA - Samyang; Celecoxib BA - Samyang; Tacrolimus BA - Samyang

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Samyang Biopharmaceuticals Corporation; Samyang Group
  • Developer Samyang Biopharmaceuticals Corporation
  • Class Benzimidazoles; Lactones; Macrolides; Morpholines; Pyrazoles; Small molecules; Sulfonamides; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcineurin inhibitors; Cyclo-oxygenase 2 inhibitors; Cytokine inhibitors; Immunosuppressants; Neurokinin 1 receptor antagonists; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Hypertension; Nausea and vomiting; Rheumatoid arthritis; Transplant rejection

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Hypertension in South Korea (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Nausea and vomiting in South Korea (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top